<DOC>
	<DOC>NCT00118638</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of darbepoetin alfa as 500ug once every 3 weeks to show that the dose and schedule are not inferior to darbepoetin alfa administered as 2.25ug/kg once per week in the treatment of anemia in subjects with non-myeloid malignancies.</brief_summary>
	<brief_title>A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Nonmyeloid malignancy At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless of schedule Eastern Cooperative Oncology Group performance status of 02 Hemoglobin concentration of less than 11 g/dL within 24 hours before randomization Of legal age at the time written informed consent is obtained Known history of seizure disorder Known primary hematologic disorder, which could cause anemia, other than a nonmyeloid malignancy Unstable or uncontrolled disease/condition, related to or affecting cardiac function Clinically significant inflammatory disease Inadequate renal and/or liver function Known positive HIV test Previously suspected of or confirmed to have neutralizing antibodies to rHuEPO Received more than 2 red blood cell (RBC) transfusions within 4 weeks before randomization or any RBC transfusion within 14 days before randomization, or any planned RBC transfusion between randomization and study day 1 Received any erythropoietic therapy within 4 weeks before randomization or any planned erythropoietic therapy between randomization and study day 1 Other investigational procedures Subject is currently enrolled in or less than 30 days since receipt of any investigational drug or device that is not approved by the applicable regulatory authority Pregnant or breast feeding Not using adequate contraceptive precautions Known sensitivity to any of the products to be administered during dosing Previously randomized in this study Concerns for subject's compliance with protocol procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Non-myeloid malignancy</keyword>
	<keyword>Darbepoetin alfa</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>